Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...
Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results